Viewing records where tag name contains "home" View All

VivaGel® BV treatment clinical submission under rolling submission

Dec 21st, 2017

Melbourne, Australia; 21 December 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has completed the VivaGel® BV treatment clinical section of the NDA clinical module, which will be submitted to the FDA under Starpharma’s rolling submission on Friday 22 December 2017 (US time). 

Read More

Starpharma annual report and full year financial results

Aug 28th, 2017

Melbourne, Australia; 28 August 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its annual report and financial results for the year ended 30 June 2017.


 

Read More

Successful VivaGel® Phase 3 results and NDA planned for rBV

Aug 7th, 2017

Starpharma today announced that its two phase 3 trials of VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data.

Read More

Sale of Agrochemicals Business Investor Presentation

Jun 14th, 2017

Melbourne, Australia; 14 June 2017: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), will be holding an investor conference call today at 11am (AEST) to discuss the sale of its Agrochemicals business to Agrium Inc., for $35 million. A presentation featuring further information on the transaction is available.

Read More

Starpharma sells Agrochemicals business to Agrium for $35M

Jun 14th, 2017

Melbourne, Australia; 14 June 2017: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals) to Agrium, Inc., (Agrium) (NYSE: AGU, TSE: AGU) for A$35 million in cash consideration. The Starpharma Agrochemical business willl be operated by Agrium’s wholly-owned subsidiary, Loveland Products, Inc.

Read More

DEP® irinotecan outperforms irinotecan in multiple cancer models

Jun 6th, 2017

Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its proprietary DEP® irinotecan has demonstrated significantly better anti‑tumour activity and increased survival compared with irinotecan in a variety of human colon cancer models. 

Read More

AstraZeneca DEP® candidate advance triggers milestone to Starpharma

Apr 20th, 2017

 Starpharma announced the achievement of a key preclinical milestone for its DEP® drug delivery technology in combination with a proprietary oncology molecule from AstraZeneca.

Read More

Ansell launches VivaGel® condom in Canada

Apr 12th, 2017

Starpharma is pleased to announce the VivaGel® condom has been launched in Canada by Ansell under the LifeStyles® Dual Protect brand. 

Read More

VivaGel® BV phase 3 trials for prevention of BV completed

Mar 30th, 2017

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced completion of its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis (rBV). Starpharma expects topline results of the trials to be available in the second quarter of 2017.

Read More

VivaGel® BV granted QIDP and Fast Track designation by US FDA

Jan 12th, 2017

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA).

Read More